Detection, prediction, and prognosis: blood circulating microRNA as novel molecular markers of head and neck cancer patients

References

• World Health Organization report. [cited 2019 Aug 10]. Available from: http://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf
   Google Scholar
• Vigneswaran N, Williams M. Epidemiological trends in head and neck cancer and aid in diagnosis. Oral Maxillofac Surg Clin North. 2014;26(2):123–141.
   PubMed Web of Science ®Google Scholar
• Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet. 2008;371:1695–1709.
   PubMed Web of Science ®Google Scholar
• Marur S, D’Souza G, Westra W, et al. HPV-associated head and neck cancer:a virus-related cancer epidemic - a review of epidemiology, biology, virus detection and issues in management. Lancet Oncol. 2010;11(8):781–789.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Chaturvedi AK, Anderson WF. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. JCO. 2015;33:3235–3242.
   PubMed Web of Science ®Google Scholar
• Jethwa AR, Khariwala SS. Tobacco-related carcinogenesis in head and neck cancer. Cancer Metastasis Rev. 2017;36(3):411–423.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Hisamatsu K, Suzui N, et al. A review of HPV-related head and neck cancer. J Clin Med. 2018;7(9):241.
   PubMed Web of Science ®Google Scholar
• Luryi AL, Yarbrough WG, Niccolai LM, et al. Public awareness of head and neck cancers a cross-sectional survey. JAMA Otolaryngol Head Neck Surg. 2014;140(7):639–646.
   PubMed Web of Science ®Google Scholar
• Canning M, Guo G, Yu M, et al. Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. Front Cell Dev Biol. 2019;7:52.
   PubMed Web of Science ®Google Scholar
• Geißler C, Hambek M, Leinung M, et al. The challenge of tumor heterogeneity–different phenotypes of cancer stem cells in a head and neck squamous cell carcinoma xenograft mouse model. In Vivo. 2012;26(4):593–598.
   PubMed Web of Science ®Google Scholar
• Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22.
   PubMed Web of Science ®Google Scholar
• Jager-Wittenaar H, Dijkstra PU, Dijkstra G, et al. High prevalence of cachexia in newly diagnosed head and neck cancer patients: an exploratory study. Nutrition. 2017;35:114–118.
   PubMed Web of Science ®Google Scholar
• Kawada T, Takahashi H, Sakakura K, et al. Circulating tumor cells in patients with head and neck squamous cell carcinoma: feasibility of detection and quantitation. Head Neck. 2017;39:2180–2186.
   PubMed Web of Science ®Google Scholar
• Hristozova T, Konschak R, Stromberger C, et al. The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region. Ann Oncol. 2011;22:1878–1885.
   PubMed Web of Science ®Google Scholar
• Kulasinghe A, Perry C, Jovanovic L, et al. Circulating tumour cells in metastatic head and neck cancers. Int J Cancer. 2015;136(11):2515–2523.
   PubMed Web of Science ®Google Scholar
• Wang Y, Springer S, Mulvey CL, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015;7(293):293ra104.
   PubMed Web of Science ®Google Scholar
• Mydlarz WK, Hennessey PT, Wang H, et al. Serum biomarkers for detection of head and neck squamous cell carcinoma. Head Neck. 2016;38:9–14.
   PubMed Web of Science ®Google Scholar
• Schröck A, Leisse A, de Vos L, et al. Free-circulating methylated DNA in blood for diagnosis, staging, prognosis, and monitoring of head and neck squamous cell carcinoma patients: an observational prospective cohort study. Clin Chem. 2017;63(7):1288–1296.
   PubMed Web of Science ®Google Scholar
• Molnár B, Tóth K, Barták BK, et al. Plasma methylated septin 9: a colorectal cancer screening marker. Expert Rev Mol Diagn. 2015;15(2):171–184.
   PubMed Web of Science ®Google Scholar
• Liang K, Yang Y, Zha D, et al. Overexpression of lncRNAsnaR is correlated with progression and predicts poor survival of laryngeal squamous cell carcinoma. J Cell Biochem. 2019;120:8492–8498.
   Web of Science ®Google Scholar
• Sun S, Gong C, Yuan K. LncRNA UCA1 promotes cell proliferation, invasion and migration of laryngeal squamous cell carcinoma cells by activating Wnt/-catenin signaling pathway. Exp Ther Med. 2019;17:1182–1189.
   PubMed Web of Science ®Google Scholar
• Sun S, Li B, Wang Y, et al. Clinical significance of the decreased expression of hsa_circ_001242 in oral squamous cell carcinoma. Dis Markers. 2018;8:6514795.
   Google Scholar
• Tan S, Gou Q, Pu W, et al. Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer. Cell Res. 2018;28(6):693–695.
   PubMed Web of Science ®Google Scholar
• Peng Y, Croce CM. The role of microRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.
   PubMed Web of Science ®Google Scholar
• Palmirotta R, Lovero D, Cafforio P, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol. 2018;10:1758835918794630.
   Web of Science ®Google Scholar
• Zeljic K, Jovanovic I, Jovanovic J, et al. MicroRNA meta-signature of oral cancer: evidence from a meta-analysis. Ups J Med Sci. 2018;123(1):43–49.
   PubMed Web of Science ®Google Scholar
• Lubov J, Maschietto M, Ibrahim I, et al. Meta-analysis of microRNAs expression in head and neck cancer: uncovering association with outcome and mechanisms. Oncotarget. 2017;8(33):55511–55524.
   PubMedGoogle Scholar
• Sethi N, Wright A, Wood H, et al. MicroRNAs and head and neck cancer: reviewing the first decade of research. Eur J Cancer. 2014;50(15):2619–2635.
   PubMed Web of Science ®Google Scholar
• Wang H, Peng R, Wang J, et al. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenet. 2018;10:59.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yu T, Cabay RJ, et al. miR-486-3p, miR-139-5p, and miR-21 as biomarkers for the detection of oral tongue squamous cell carcinoma. Biomark Cancer. 2017;9:1–8.
   PubMedGoogle Scholar
• Erkul L, Yilmaz I, Gungor A, et al. MicroRNA‐21 in laryngeal squamous cell carcinoma: diagnostic and prognostic features. Laryngoscope. 2017;127(2):62–66.
   PubMed Web of Science ®Google Scholar
• Gombos K, Horvath R, Szele E, et al. MiRNA expression profiles of oral squamous cell carcinomas. Anticancer Res. 2013;33(4):1511–1517.
   PubMed Web of Science ®Google Scholar
• Wang JI, Wang X, Yang D, et al. The expression of microRNA-155 in plasma and tissue is matched in human laryngeal squamous cell carcinoma. Yonsei Med J. 2016;57(2):298–305.
   PubMed Web of Science ®Google Scholar
• Schneider A, Victoria B, Lopez YN, et al. Tissue and serum microRNA profile of oral squamous cell carcinoma patients. Sci Rep. 2018;8:675.
   PubMed Web of Science ®Google Scholar
• Hsu CM, Lin PM, Wang YM, et al. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumor Biol. 2012;33:1933–1942.
   PubMedGoogle Scholar
• Steuer CE, El-Deiry M, Parks JR, et al. An update on larynx cancer. CA Cancer J Clin. 2017;67:31–50.
   PubMed Web of Science ®Google Scholar
• Zhang E, Feng X, Feng Y. MicroRNA-21-3p serves as a novel biomarker for diagnosis of laryngeal cancer. Int J Clin Exp Pathol. 2016;9(11):12136–12141.
   Web of Science ®Google Scholar
• Zhou B, Dai LL, Xu P, et al. MicroRNA-27a acts as a novel biomarker in the diagnosis of patients with laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 2016;9(2):2049–2053.
   Web of Science ®Google Scholar
• Wang LL, Li HX, Yang YY, et al. MiR-31 is a potential biomarker for diagnosis of head and neck squamous cell carcinoma. Int J Clin Exp Pathol. 2018;11(9):4339–4345.
   PubMed Web of Science ®Google Scholar
• Grzelczyk WL, Szemraj J, Kwiatkowska S, et al. Serum expression of selected miRNAs in patients with laryngeal squamous cell carcinoma (LSCC). Diagn Pathol. 2019;14:49.
   PubMed Web of Science ®Google Scholar
• Chang YA, Weng SL, Yang SF, et al. A three–microRNA Signature as a potential biomarker for the early detection of oral cancer. Int J Mol Sci. 2018;19:758.
   Web of Science ®Google Scholar
• Liu X, Luo HN, Tian WD, et al. Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma. Cancer Biol Ther. 2013;14(12):1133–1142.
   PubMed Web of Science ®Google Scholar
• Wen W, Mai SJ, Lin HX, et al. Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma. J Transl Med. 2019;17:186.
   PubMed Web of Science ®Google Scholar
• Zeng X, Xiang J, Wu M, et al. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One. 2012;7(10):e46367.
   PubMed Web of Science ®Google Scholar
• Ries J, Vairaktaris E, Agaimy A, et al. miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 2014;31(3):1429–1436.
   PubMed Web of Science ®Google Scholar
• Zheng XH, Cui C, Ruan HL, et al. Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers. Chin J Cancer. 2014;33(7):330–338.
   PubMedGoogle Scholar
• Lu Z, He Q, Liang J, et al. miR-31-5p is a potential circulating biomarker and therapeutic target for oral cancer. Mol Ther Nucleid Acids. 2019;16:471–480.
   Web of Science ®Google Scholar
• Liu CJ, Kao SY, Tu HF, et al. Increase of microRNAmiR-31 level in plasma could be apotential marker of oral cancer. Oral Dis. 2010;16:360–364.
   PubMed Web of Science ®Google Scholar
• Lu YC, Chang J, Huang YC, et al. Combined determination of circulating miR-196a and miR-196b levelsproduces high sensitivity and specificity for early detection of oral cancer. Clin Biochem. 2015;48(3):115–121.
   PubMed Web of Science ®Google Scholar
• Khawar MB, Fatima N, Hassan M, et al. Head and neck cancer: epidemiology and role of microRNAs. In: Diagnosis and management of head and neck cancer. Zuhre Akarslan, IntechOpen. 2017:5–35. Doi: 10.5772/intechopen.69418.
   Google Scholar
• Ishinaga H, He F, Hou B, et al. A longitudinal study on circulating miR-21 as a therapeutic effect marker in head and neck squamous cell carcinoma. Carcinogenesis. 2019. DOI:10.1093/carcin/bgz075.
   PubMed Web of Science ®Google Scholar
• Summerer I, Unger K, Braselmann H, et al. Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients. Br J Cancer. 2015;113(1):76–82.
   PubMed Web of Science ®Google Scholar
• Summerer I, Niyazi M, Unger K, et al. Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol. 2013;8:296.
   PubMed Web of Science ®Google Scholar
• Xu X, Lu J, Wang F, et al. Dynamic changes in plasma microRNAs have potential predictive values in monitoring recurrence and metastasis of nasopharyngeal carcinoma. Biomed Res Int. 2018;7329195.
   PubMed Web of Science ®Google Scholar
• Hou B, Ishinaga H, Midorikawa K, et al. Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma. Cancer Biol Ther. 2015;16:1042–1046.
   PubMed Web of Science ®Google Scholar
• Higgins KA, Saba NF, Shin DM, et al. Circulating Pre-treatment miRNAs as potential biomarkers to predict radiation toxicity. Int J Radiat Oncol Biol Phys. 2017;99(2):E596.
   PubMed Web of Science ®Google Scholar
• Nakashima H, Yoshida R, Hirosue A, et al. Circulating miRNA-1290 as a potential biomarker for response to chemoradiotherapy and prognosis of patients with advanced oral squamous cell carcinoma: A single-center retrospective study. Tumor Biol. 2019. DOI:10.1177/1010428319826853.
   PubMedGoogle Scholar
• He Y, Zhang L, Cheng G, et al. Upregulation of circulating miR-21 is associated with poor prognosis of nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2017;10(7):7362–7368.
   PubMed Web of Science ®Google Scholar
• Chen L, Wen Y, Zhang J, et al. Prediction of radiotherapy response with a 5‐microRNA signature‐based nomogram in head and neck squamous cell carcinoma. Cancer Med. 2018;7(3):726–735.
   PubMed Web of Science ®Google Scholar
• Ahmad P, Sana J, Slavik M, et al. MicroRNAs involvement in radioresistance of head and neck cancer. Dis Markers. 2017;2017:8245345.
   PubMed Web of Science ®Google Scholar
• Chen X, Xu Y, Liao X, et al. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer. Tumour Biol. 2016;37:11927–11936.
   PubMed Web of Science ®Google Scholar
• Bi N, Schipper MJ, Stanton P, et al. Serum miRNA signature to identify a patient’s resistance to high-dose radiation therapy for unresectable non-small cell lung cancer. J Clin Oncol. 2013;31(suppl):7580.
   Google Scholar
• Kumarasamy C, Madhav MR, Sabarimurugan S, et al. Prognostic value of miRNAs in head and neck cancers: a comprehensive systematic and meta-analysis. Cells. 2019;8(8):772.
   Web of Science ®Google Scholar
• Kumarasamy C, Devi A, Jayaraj R. Prognostic value of microRNAs in head and neck cancers: a systematic review and meta-analysis protocol. Syst Rev. 2018;7:150.
   PubMed Web of Science ®Google Scholar
• Sun L, Liu L, Fu H, et al. Association of decreased expression of serum mir-9 with poor prognosis of oral squamous cell carcinoma patients. Med Sci Monit. 2016;22:289–294.
   PubMed Web of Science ®Google Scholar
• Shi J, Bao X, Liu Z, et al. Serum miR-626 and miR-5100 are promising prognosis predictors for oral squamous cell carcinoma. Theranostics. 2019;9(4):920–931.
   PubMed Web of Science ®Google Scholar
• Guo L, Cai X, Hu W, et al. Expression and clinical significance of miRNA-145 and miRNA-218 in laryngeal cancer. Oncol Lett. 2019;18:764–770.
   PubMed Web of Science ®Google Scholar
• Xu H, Yang Y, Zhao H, et al. Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma. Tumor Biol. 2016;37:447–453.
   PubMed Web of Science ®Google Scholar
• Liu CJ, Lin JS, Cheng HW, et al. Plasma miR-187* is a potential biomarker for oral carcinoma. Clin Oral Invest. 2017;21:1131–1138.
   PubMed Web of Science ®Google Scholar
• Rapado-Gonzales O, Majem B, Muinelo-Romay L, et al. Human salivary microRNAs in cancer. J Cancer. 2018;9(4):638–649.
   PubMed Web of Science ®Google Scholar
• Salazar C, Nagadia R, Pandit P, et al. A novel saliva-based microRNA biomarker panel to detect head and neck cancers. Cell Oncol. 2014;37(5):331–338.
   PubMed Web of Science ®Google Scholar
• Momen-Heravi F, Trachtenberg AJ, Kuo WP, et al. Genomewide study of salivary microRNAs for detection of oral cancer. J Dent Res. 2014;93(Suppl 7):S86–S93.
   Web of Science ®Google Scholar
• Zahran F, Ghalwash D, Shaker O, et al. Salivary microRNAs in oral cancer. Oral Dis. 2015;21(6):739–747.
   PubMed Web of Science ®Google Scholar
• Poel D, Buffart TE, Oosterling-Jansen J, et al. Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. Exp Mol Med. 2018;50:e454.
   PubMed Web of Science ®Google Scholar
• Moody L, He H, Pan YX, et al. Methods and novel technology for microRNA quantification in colorectal cancer screening. Clin Epigenetics. 2017;9:119.
   PubMed Web of Science ®Google Scholar
• Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer (review). Biomed Rep. 2016;5(4):395–402.
   PubMed Web of Science ®Google Scholar
• Yu T, Ma P, Wu D, et al. Functions and mechanisms of microRNA-31 in human cancers. Biomed Pharmacother. 2018;108:1162–1169.
   PubMed Web of Science ®Google Scholar
• Peng Q, Zhang X, Min M, et al. The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(27):44893–44909.
   PubMedGoogle Scholar